Aprea Therapeutics, Inc.
APRE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.02 | 0.07 | -0.10 |
| FCF Yield | -30.45% | -29.70% | -17.92% | -15.11% |
| EV / EBITDA | 1.85 | 1.73 | 1.01 | 2.42 |
| Quality | ||||
| ROIC | -23.96% | -24.23% | -15.65% | -17.62% |
| Gross Margin | 95.40% | 0.00% | 97.36% | 98.47% |
| Cash Conversion Ratio | 1.10 | 0.97 | 0.92 | 1.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.98% | 49.90% | 1,086,930.89% | 1,145,270.42% |
| Free Cash Flow Growth | 13.78% | -3.43% | -42.24% | 30.40% |
| Safety | ||||
| Net Debt / EBITDA | 4.88 | 4.72 | 7.09 | 6.42 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -19,827.82 | 0.00 | -10,618.76 | 0.00 |